Physician profile
Jaskarn Johl
NPI 1245492677
$8,533.91
in general payments reported to CMS, 2019-2025
26 companies · $1,307 in 2025
The $1,307 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $747 · 2021: $1,109 · 2022: $1,265 · 2023: $1,910 · 2024: $1,671 · 2025: $1,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,803 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,803.12 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,395.66 | 2019-2025 | Clareon, Rocklatan, Simbrinza |
| Dompe US, INC. | $965.51 | 2021-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $871.87 | 2021-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $686.54 | 2020-2025 | Acthar |
| Allergan, INC. | $635.29 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $528.53 | 2019-2021 | |
| Lumenis Be INC | $512.49 | 2023 | M22 |
| Sight Sciences, INC. | $427.63 | 2019-2024 | Omni Surgical System |
| Ani Pharmaceuticals, INC. | $422.10 | 2023-2024 | Purified Cortrophin Gel |
| Tarsus Pharmaceuticals, INC. | $398.18 | 2024-2025 | Xdemvy |
| Amgen INC. | $336.09 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $252.91 | 2020-2022 | |
| Merz Pharmaceuticals, LLC | $228.21 | 2022 | |
| Oyster Point Pharma, INC. | $132.40 | 2024-2025 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $131.43 | 2020-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $121.13 | 2019 | |
| Glaukos Corporation | $114.48 | 2019-2025 | Idose, Idosetr, Istent Infinite |
| Harrow Eye, LLC | $90.94 | 2024-2025 | Vevye, Iheezo |
| Kala Pharmaceuticals, INC. | $64.85 | 2021-2022 | |
| Genentech USA, INC. | $52.27 | 2022 | |
| Rxsight INC | $41.05 | 2021-2025 | Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Bausch & Lomb Americas INC. | $32.75 | 2024 | Xiidra |
| Optos, INC. | $28.84 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $23.40 | 2025 | Tecnis Simplicity |
| Biotissue Holdings INC. | $19.96 | 2024 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaskarn Johl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.